mRNA-1645-CoreG28v2

Phase 1RNA therapy

IInternational AIDS Vaccine Initiative

mRNA-1645-CoreG28v2 is one of 15 biologic programs targeting HIV Infections. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

HIV InfectionsActive, not recruiting

HIV InfectionsPhase 1

Active, not recruiting

Competition

Competitive Landscape

43 competitors in HIV Infections

#DrugCompanyPhaseTrials

Biktarvy

Gilead

Approved

1 2

Sunlenca

Gilead

Phase 3

2 3

Cabenuva

GSK

Phase 3

2 4

Edurant Ped

WWim Janssens

Phase 3

1 5

CAB LA

GSK

Phase 3

1 6

Teropavimab

Gilead

Phase 3

1 7

Zinlirvimab

Gilead

Phase 3

1 8

Tenofovir Disoproxil and Emtricitabine

RRutgers, The State University of New Jersey

Phase 3

1 9

Sprycel

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 1

1 10

Versed

CConrado Roberto Hoffmann Filho

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 1Active, not recruiting

HIV Infections

NCT06694753

Clinical

Trials by Indication[1]

HIV Infections1 trial

A Phase 1, Placebo-controlled, Blinded, Dose-escalation Study to Evaluate the Safety and Immunogenicity of mRNAs Encoding HIV Immunogens (eOD-GT8 60mer, Core-g28v2 60mer, N332-GT5 gp151) in Adult Participants Without HIV and in Overall Good Health in South Africa.

Active, not recruiting·IInternational AIDS Vaccine Initiative·Phase 1·NCT06694753·96 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for mRNA-1645-CoreG28v2. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — mRNA-1645-CoreG28v2 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for mRNA-1645-CoreG28v2. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — International AIDS Vaccine Initiative company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: RNA therapy[2]
Highest Phase: Phase 1[1]
Company: IInternational AIDS Vaccine Initiative

mRNA-1645-CoreG28v2

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Trials by Indication[1]

HIV Infections1 trial

References

Drug Info

Quick Facts

Related News